Olaparib
- Generic Name
- Olaparib
- Brand Names
- Lynparza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23FN4O3
- CAS Number
- 763113-22-0
- Unique Ingredient Identifier
- WOH1JD9AR8
- Background
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...
- Indication
Ovarian cancer
Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
- Associated Therapies
- Maintenance therapy
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 152
- Registration Number
- NCT06298084
- Locations
- 🇫🇷
Gustave Roussy Institut, Villejuif, France
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06245889
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 45
- Registration Number
- NCT06217757
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 176
- Registration Number
- NCT06201234
- Locations
- 🇩🇪
Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt Am Main, Hessen, Germany
🇩🇪MVZ für Hämatologie und Onkologie Ravensburg GmbH Studienzentrum, Ravensburg, Germany
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 18
- Registration Number
- NCT06177171
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination with the PARP Inhibitor Olaparib in Patients with KRAS G12C Mutated Advanced Solid Tumors, with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06130254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 190
- Registration Number
- NCT06121401
- Locations
- 🇮🇹
Azienda Socio Sanitaria Territoriale (ASST) Lariana, San Fermo Della Battaglia, Como, Italy
🇮🇹Istituto Oncologico Veneto IRCCS, Padova, Italy
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Tango Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06065059
- Locations
- 🇺🇸
New York University Langone Health, New York, New York, United States
🇺🇸Mid Florida Cancer Centers, Orange City, Florida, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05967286
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.